Insider Selling: Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Insider Sells $263,350.00 in Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) insider Helen Louise Collins sold 5,000 shares of the business’s stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $52.67, for a total value of $263,350.00. Following the sale, the insider owned 25,000 shares of the company’s stock, valued at $1,316,750. The trade was a 16.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins also recently made the following trade(s):

• On Wednesday, June 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $43.80, for a total transaction of $219,000.00.

Bitwise MARA Option Income Strategy ETF Stock Performance

NYSEARCA IMRA opened at $14.52 on Friday. The firm has a market capitalization of $1.89 million, a price-to-earnings ratio of 290.40 and a beta of 2.74. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $42.32. The company’s 50 day moving average price is $16.41 and its 200 day moving average price is $15.46.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.